Dec. 1 at 6:11 PM
$CLLS
On December 4, Cellectis is hosting a webinar dedicated to French shareholders to provide an update on our recent scientific, clinical and strategic developments, including:
📍 The promising Phase 1 clinical data presented at the R&D Day on October 16, 2025 for lasme-cel, as well as the pivotal Phase 2 design.
📍The commercial potential of lasmé-cel (up to approximately
$700 million in annual gross sales at its peak).
📍The next steps for our eti-cel.
📍A review of our strategic partnerships.
📍Our recent advances in genome editing.
The presentation will be followed by a Q&A session with the executives.
❓ Submit your questions in advance to: mailto:
[email protected]
👉 Registration required – link in first comment.
